NEW YORK, March 2, 2017 /PRNewswire/ --
Stock-Callers.com directs investors' attention today to the Healthcare sector which includes health care providers and services, health care equipment and supplies, and health care technology companies. Companies in this sector are involved in the research, development, production, and marketing of pharmaceuticals and biotechnology products. Equities under evaluation this morning are: Novan Inc. (NASDAQ: NOVN), Acceleron Pharma Inc. (NASDAQ: XLRN), and Meridian Bioscience Inc. (NASDAQ: VIVO). These stocks research reports can be downloaded now by simply registering for free at:
On Wednesday, Durham, North Carolina headquartered Novan Inc.'s stock recorded a trading volume of 253,627 shares, and ended the session 4.59% higher at $5.92. The Company's shares have surged 34.55% in the last one month. The stock is trading 62.53% below its 50-day moving average. Moreover, shares of Novan, which focuses on the development and commercialization of nitric oxide-based therapies in dermatology, have a Relative Strength Index (RSI) of 33.73.
On March 01st, 2017, Novan announced that preclinical data demonstrating the anti-viral effects of its nitric oxide-releasing drug candidates will be presented at the 31st International Papillomavirus Conference in Cape Town, South Africa. Thomas Broker, Ph.D., and Louise Chow, Ph.D., both of the University of Alabama at Birmingham, or UAB, are scheduled to present "Antiviral Efficacy of Nitric Oxide-Releasing Drug Candidates in Suppressing Productive Infection by HPV-18 in the Organotypic Epithelial Raft Culture Model System" on March 02nd, 2017. Drs. Broker and Chow are professors in the Department of Biochemistry and Molecular Genetics at UAB's School of Medicine. Your complete research report on NOVN can be retrieved for free at:
Cambridge, Massachusetts headquartered Acceleron Pharma Inc.'s stock closed the day 7.37% higher at $28.69. A total volume of 778,029 shares was traded, which was above their three months average volume of 410,520 shares. The Company's shares have advanced 22.40% in the past month and 12.42% on an YTD basis. The stock is trading 11.46% above its 50-day moving average. Additionally, shares of Acceleron Pharma, which focuses on the discovery, development, and commercialization of protein therapeutics for cancer and rare diseases, have an RSI of 68.20.
On March 01st, 2017, Acceleron reported that cash, cash equivalents, and investments were $234.4 million as of December 31st, 2016. The Company's collaboration revenue for FY16 was $27.8 million. The Company stated that all of revenue is generated from its Celgene partnership. It includes license and milestone revenue of $15.6 million and cost sharing revenue of $12.2 million related to expenses incurred by the Company in support of its partnered programs. The Company's net loss for the year ended December 31st, 2016 was $57.0 million. A free report on XLRN is just a click away at:
Shares in Cincinnati, Ohio headquartered Meridian Bioscience Inc. recorded a trading volume of 568,705 shares, which was above their three months average volume of 457,200 shares. The stock ended yesterday's trading session 1.17% higher at $13.00. The Company's shares have advanced 1.38% in the past month. The stock is trading below its 50-day moving average by 13.61%. Furthermore, shares of Meridian Bioscience, which develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal, viral, respiratory, and parasitic infectious diseases worldwide, have an RSI of 42.05.
On February 08th, 2017, Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience announced the expansion of the JetSeq(TM) DNA Library Preparation portfolio for Next Generation Sequencing (NGS) sample preparation. Developed in collaboration with Oxford Gene Technology, the new JetSeq(TM) DNA Library Preparation Kits use pre-optimized buffers to provide maximum reaction efficiency and highest conversion rates, enabling the preparation of the highest quality NGS sequencing-ready, adapter-ligated DNA for Illumina`s Next Generation Sequencers. Sign up for your complimentary research report on VIVO at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA